Literature DB >> 16823717

Charcot foot in diabetes: farewell to the neurotrophic theory.

E Chantelau1, G J Onvlee.   

Abstract

Neuropathic osteoarthropathy is characterised by relatively painless swelling together with extensive damage in bones and joints, predominantly in the feet and ankles. The uncontrolled natural course of the condition leads to gross foot deformity, skin pressure ulceration, spreading infections, and sometimes amputation. Jean-Martin Charcot in 1883 described "Charcot foot" named after him in patients with tabes dorsalis insensitivity. Charcot believed that intrinsic bone weakness was the underlying condition, and was caused by neurogenic deficiencies in bone nutrition. His followers believed such dystrophy to be mediated by sympathetic denervation of the bone vasculature (neurotrophic, or neurovascular theory). Attempts to prove this theory were futile. A neurogenic circulatory disorder potentially relevant to bone nutrition could not be identified. Nowadays, Charcot foot is mostly seen in diabetic neuropathy, which has replaced syphilis as a frequent cause of peripheral nerve dysfunction. Recent studies in the diabetic Charcot foot and bone turnover indicate that the neurotrophic theory is a myth. The assumption of bone resorption due to sympathetic denervation proved to be false--sympathetic activity increases osteoclastic activity and thereby bone loss (sympathomimetic bone resorption). Except for the transient, inflammatory stage of the diabetic Charcot foot, there is no evidence of relevant osteoporosis or demineralisation of the foot skeleton in diabetes.

Entities:  

Mesh:

Year:  2006        PMID: 16823717     DOI: 10.1055/s-2006-944525

Source DB:  PubMed          Journal:  Horm Metab Res        ISSN: 0018-5043            Impact factor:   2.936


  21 in total

1.  Overlapping features of rapidly progressive osteoarthrosis and Charcot arthropathy.

Authors:  Takashi Sono; Carolyn A Meyers; Daniel Miller; Catherine Ding; Edward F McCarthy; Aaron W James
Journal:  J Orthop       Date:  2019-03-12

Review 2.  [Problems and controversies in the treatment of ankle fractures].

Authors:  S Rammelt; D Heim; L C Hofbauer; R Grass; H Zwipp
Journal:  Unfallchirurg       Date:  2011-10       Impact factor: 1.000

3.  [The Midfoot Fusion Bolt: a new perspective?].

Authors:  M Wurm; R Schuh; A Wanivenhaus; R Windhager; H-J Trnka
Journal:  Orthopade       Date:  2015-01       Impact factor: 1.087

4.  [Pathophysiology and etiology of the Charcot foot].

Authors:  K Trieb; S G Hofstätter
Journal:  Orthopade       Date:  2015-01       Impact factor: 1.087

Review 5.  [Surgical treatment of the Charcot foot : long-term results and systematic review].

Authors:  N Hartig; S Krenn; H-J Trnka
Journal:  Orthopade       Date:  2015-01       Impact factor: 1.087

Review 6.  The Charcot foot as a complication of diabetic neuropathy.

Authors:  Janice V Mascarenhas; Edward B Jude
Journal:  Curr Diab Rep       Date:  2014-12       Impact factor: 4.810

7.  Routine MRI findings of the asymptomatic foot in diabetic patients with unilateral Charcot foot.

Authors:  Ludger W Poll; Ernst A Chantelau
Journal:  Diabetol Metab Syndr       Date:  2010-04-22       Impact factor: 3.320

Review 8.  [Charcot foot. Current situation and outlook].

Authors:  T Mittlmeier; K Klaue; P Haar; M Beck
Journal:  Unfallchirurg       Date:  2008-04       Impact factor: 1.000

9.  Outcomes of surgical treatment of diabetic foot osteomyelitis: a series of 185 patients with histopathological confirmation of bone involvement.

Authors:  F J Aragón-Sánchez; J J Cabrera-Galván; Y Quintana-Marrero; M J Hernández-Herrero; J L Lázaro-Martínez; E García-Morales; J V Beneit-Montesinos; D G Armstrong
Journal:  Diabetologia       Date:  2008-08-22       Impact factor: 10.122

10.  Diabetic bone lesions: a study on 38 known modern skeletons and the implications for forensic scenarios.

Authors:  Lucie Biehler-Gomez; Elisa Castoldi; Elisa Baldini; Annalisa Cappella; Cristina Cattaneo
Journal:  Int J Legal Med       Date:  2018-06-02       Impact factor: 2.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.